An 83-year-old woman presented to our emergency department with mild dyspnoea. The patient had been in her usual state of health until 3 days prior to admission. Her medical history revealed no specific illness, and she was a never-smoker.

The patient’s vital signs were within normal range, and physical examination revealed decreased breath sounds in the right lower lung field. Arterial blood gas analysis showed an oxygen saturation of 97%, a partial oxygen pressure of 11.7 kPa and a partial carbon dioxide pressure of 4.9 kPa. Laboratory tests demonstrated a leucocyte count of 1.5x10⁹/L, 76.8% of which were neutrophils, an erythrocyte sedimentation rate of 53 mm/hour and a high-sensitivity C-reactive protein level of 150.87 mg/L, suggesting the presence of an underlying inflammatory reaction. Laboratory examinations, including chemistry panels, were otherwise normal.

A chest X-ray showed highly increased density in the right lung field (figure 1A, B). Chest CT displayed an 8.3×7.1 mm endobronchial mass.

**Figure 1** (A) and (B) Chest X-ray showing highly increased density in the right lung field. (C) Contrast-enhanced CT displaying an 8.3×7.1-mm endobronchial mass with low heterogeneous enhancement, completely obstructing the right middle lobar bronchus (arrow). There is a total consolidation of the right middle lobe without a decrease in volume, suggesting the presence of obstructive atelectasis. (D) 2-Deoxy-2-[¹⁸F]-fluoro-D-glucose (FDG) positron emission tomography/CT revealing a nodular lesion obstructing the right middle lobar bronchus without obvious FDG uptake (inset, arrow). There is also obstructive pneumonitis with diffuse FDG uptake extending distally to the mass. (E) Diagnostic bronchoscopy showing a smooth surfaced and hypervascular mass which is obstructing the entrance of the right middle lobe. (F) H&E staining of the endobronchial mass specimen demonstrating the biphasic morphology, comprising an inner layer of duct-like structures with epithelial cells and a surrounding layer of myoepithelial cells with spindle-shaped cells and clear cells (×200). Bar indicates scale of 25 μm. (G–I) Immunohistochemical staining of the endobronchial mass specimen. The inner layer composed of epithelial cells is positive for cytokeratin (G, ×400), whereas the surrounding layer with myoepithelial cells is positive for actin (H, ×400). The entire specimen is negative for thyroid transcription factor 1 (I, ×200). Bars indicate scale of 25 μm.
that completely obstructed the right middle lobe bronchus. In addition, there was concurrent obstructive pneumonitis extending distally to the endobronchial mass (figure 1C). No lymph node enlargement was detected in the mediastinum. 2-Deoxy-2-(18F)-fluoro-D-glucose (FDG) positron emission tomography (PET)/CT revealed a nodular lesion obstructing the right middle lobe bronchus without obvious FDG uptake (figure 1D). There was no abnormal glucose uptake in the other parts of the body.

Bronchoscopic examination showed a smooth surfaced and hypervascular mass, totally obstructing the entrance of the right middle lobe (figure 1E). A biopsy specimen from the mass displayed duct-like structures composed of an inner layer of cuboidal-shaped cells with eosinophilic cytoplasm and a surrounding spindle-shaped cell layer with clear cytoplasm (figure 1F). Immunohistochemical staining confirmed this biphasic differentiation, as the inner layer was positive for epithelial markers, such as cytokeratin (figure 1G), and the surrounding layer was positive for myoepithelial markers, including actin (figure 1H), vimentin and S-100. Both the epithelial and myoepithelial cells were negative for thyroid transcription factor 1 (figure 1I). Based on these results, the mass was diagnosed as an epithelial-myoepithelial carcinoma (EMC) of the lung. Further evaluation and treatment could not be performed due to patient refusal.

Interestingly, in our case, EMC of the lung showed insignificant glucose uptake in PET/CT. The utility of PET/CT in evaluating histological differentiation has been reported previously in the salivary gland malignancies, which seems to show a tendency that histological grade of malignancy is proportional to the level of glucose uptake in FDG PET/CT. This characteristic feature might be correlated with the low-grade malignant potential, considering the histological homology with EMC of the salivary glands. However, caution should be taken to differentiate EMC of the lung from benign endobronchial tumours showing low FDG uptake, such as carcinoid tumours, hamartoma, schwannoma and neurofibroma.

In summary, our experience highlights the importance of considering pulmonary EMC as one possible diagnosis in patients with an endobronchial mass showing low or no FDG uptake.

Acknowledgements This study was performed under a project entitled "Medical school students training program: Dream of being a Nobel Prize Winner," part of the Research Center for Pulmonary Disorders at the Chonbuk National University Medical School and Research Institute of Clinical Medicine of the Chonbuk NationalUniversity-Biomedical Research Institute at the Chonbuk National University Hospital.

Contributors CHK and JSJ wrote the manuscript and reviewed the previous literature. JSI, SRK and YCL cared for the patient and established the diagnosis. YCL, as a corresponding author, is responsible for all the documents and figure regarding this publication.

Funding This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Information and Communication Technology (ICT) and Future Planning (NRF-2014R1A2A1A01002823), and by funds from the Biomedical Research Institute, Chonbuk National University Hospital.

Competing interests None declared.

Patient consent Obtained.

Ethics approval The Institutional Review Board of the Chonbuk National University Hospital stated that it was not necessary to achieve IRB approval for this case report, but that patient consent was required as the study dealt with retrospective use of patient medical records and related images.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
Endobronchial epithelial-myoepithelial carcinoma of the lung

Chang Hoon Kim, Jae Seok Jeong, So Ri Kim and Yong Chul Lee

Thorax published online December 1, 2017

Updated information and services can be found at: http://thorax.bmj.com/content/early/2017/12/01/thoraxjnl-2017-211155

These include:

References
This article cites 6 articles, 1 of which you can access for free at: http://thorax.bmj.com/content/early/2017/12/01/thoraxjnl-2017-211155

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (270)
Theorax Images in Thorax (164)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/